What is the recommended regimen to prevent cisplatin‑induced nephrotoxicity?

Nephrotoxicity-Alleviating Regimen for Cisplatin

Aggressive intravenous saline hydration before and after each cisplatin infusion is the cornerstone of nephrotoxicity prevention and must be administered to all patients receiving cisplatin. 1

Core Hydration Protocol

Administer adequate intravenous fluids both prior to and following every cisplatin cycle to reduce nephrotoxicity incidence. 1 The evidence supports flexibility in hydration approaches:

• Short-duration, low-volume outpatient hydration regimens are safe and effective, even for intermediate- to high-dose cisplatin. 2
• Outpatient intravenous fluid support is typically required for 5–7 days after chemotherapy to prevent dehydration and maintain renal perfusion. 1
• Short hydration protocols have demonstrated significantly lower nephrotoxicity rates compared to conventional prolonged hydration (14.4% vs 33.1% creatinine increase ≥ grade 1). 3

Magnesium Supplementation

Add magnesium sulfate (8–20 mEq) to the hydration regimen as a nephroprotective strategy:

• Magnesium-supplemented hydration (20 mEq in 1000 mL saline over 3 hours pre-cisplatin) was the only independent protective factor against cisplatin nephrotoxicity in multivariate analysis (OR 0.157,95% CI 0.030–0.670). 4
• Magnesium supplementation (8–16 milliequivalents) may limit cisplatin-induced nephrotoxicity and represents a best practice principle. 2

Forced Diuresis with Mannitol

Consider mannitol for select high-risk patients, though evidence remains preliminary:

• Mannitol forced diuresis may be appropriate in patients receiving high-dose cisplatin and/or those with preexisting hypertension. 2
• Preliminary trends from three small trials (n=164) suggest mannitol might reduce severe AKI (grade ≥2), particularly versus placebo, but this evidence is insufficient for routine implementation and should be considered hypothesis-generating. 5

Pharmacologic Nephroprotection: Amifostine

Amifostine may be used to reduce cumulative cisplatin-related nephrotoxicity in patients with advanced ovarian cancer or non-small-cell lung cancer receiving repeated cisplatin doses. 1

• FDA approval is limited to this specific indication; it is not approved for curative-intent regimens except within clinical trials. 1
• Current data do not indicate that amifostine compromises antitumor efficacy of cisplatin-based chemotherapy. 1

Mandatory Pre-Treatment Requirements

Baseline normal renal function is required before initiating cisplatin-based therapy. 1

• Estimate glomerular filtration rate (GFR) to determine cisplatin eligibility. 1
• If GFR < 60 mL/min, substitute carboplatin for cisplatin, except in the peri-operative setting where substitution is not recommended. 1

Monitoring and Dose Modifications

Monitor renal function, electrolytes, and signs of myelosuppression or dehydration after each cycle; delay dosing until values return to baseline. 1

• In patients with borderline renal function, consider split-dose cisplatin schedules (e.g., 35 mg/m² on days 1 and 2 or days 1 and 8), though efficacy is undefined (Category 2B). 1

Critical Medication Interactions to Avoid

Avoid concurrent nephrotoxic agents, which increase acute kidney injury risk:

• The "triple-whammy" combination of renin-angiotensin system inhibitors, diuretics, and NSAIDs is specifically associated with higher AKI risk and should be avoided. 1
• Concurrent aminoglycosides, NSAIDs, or iodinated contrast media increase nephrotoxicity risk. 6

Practical Implementation Algorithm

1. Verify GFR ≥ 60 mL/min before first dose 1
2. Discontinue nephrotoxic medications (NSAIDs, ACE-I/ARB + diuretics if possible) 1
3. Administer magnesium sulfate 20 mEq in 1000 mL saline over 3 hours pre-cisplatin 4
4. Infuse cisplatin per protocol 1
5. Continue outpatient IV hydration for 5–7 days post-chemotherapy 1
6. Consider amifostine if advanced ovarian/NSCLC with repeated cisplatin exposure 1
7. Monitor creatinine and electrolytes before each subsequent cycle 1